Ensysce Biosciences Inc. (ENSC) - Cash on Hand per Share

Ensysce Biosciences (ENSC) is developing innovative TAAP/MPAR systems to combat the opioid crisis. Ownership of patents for safe analgesics provides high growth potential. However, the lack of sales leaves the company dependent on external financing and FDA verdicts. The cash per share metric illustrates liquidity dynamics, where the 1.53 mark indicates the level of current capital reserves.
Analytical breakdowns for Ensysce Biosciences

The development of safe TAAP analgesics requires significant capital expenditures for clinical trials. By analyzing the cash per share chart, an investor assesses the liquidity of Ensysce Biosciences (ENSC). This metric is calculated as the ratio of total cash to the total number of shares outstanding. It determines the actual asset value available to each share. A high level of this indicator guarantees the biotech's financial stability during the period leading up to product commercialization.